## Veozah® (fezolinetant) – Boxed warning added

- On December 16, 2024, the FDA approved a label update to Astellas' Veozah (fezolinetant), **adding a *Boxed Warning* for the risk of hepatotoxicity**.
    - In September 2024, the FDA added a warning about the risk of liver injury and required liver blood testing in the prescribing information for Veozah. **The new update elevates this risk to a *Boxed Warning*, which is the FDA's most prominent warning**.
- The FDA update was based on a review of a post marketing report of a patient with elevated liver blood test values and signs and symptoms of liver injury after taking the medicine for about 40 days.
- Veozah is a neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
- Healthcare professionals should conduct **hepatic laboratory testing before prescribing Veozah**, then every month for the first three months after patients start treatment, and then at months 6 and 9 of treatment.